Cambridge Cog Regulatory News (COG)

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

David Cameron references Cambridge Cognition in speech at G8 Dementia Summit

Cambridge Cognition (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, is pleased to note that Cambridge Cognition was mentioned in Prime Minister David Cameron's speech at the G8 Dementia Summit, held in London on 11 December.

The Prime Minister identified Cambridge Cognition as one of the companies working to develop new tests for Alzheimer's Disease. The link to the full speech can be found here:

https://www.gov.uk/government/speeches/g8-dementia-summit-prime-ministers-speech 

The G8 Dementia Summit gathered health ministers from around the world to develop co-ordinated global action on dementia. The G8 Dementia Summit was launched in March 2012 by Prime Minister David Cameron to co-ordinate a response to the issues faced by the ageing population.

The Alzheimer's Society has promised to spend at least £100m on research in the next decade and the Medical Research Council ('MRC') will commit £50m to improve treatments and delay the progression of the disease.

Chief Scientific Officer at Cambridge Cognition, Dr Andrew Blackwell, commented: "The commitment to continued research into dementia is vital if we are to make significant progress in finding new ways of managing the condition. There is still much to be done and more support needed for our healthcare services who deal with detecting, diagnosing and managing the condition every day."

Commenting on the results Nick Kerton, Chief Executive Officer, said: "We are delighted to be mentioned as one of the companies working to develop new tests for Alzheimers by David Cameron's G8 Dementia Summit speech. This demonstrates that we are at the forefront of the sector strengthening our profile in the dementia space.

Cambridge Cognition's CANTABmobile cognitive testing software and its involvement in the government funded Brain Health Centre pilot project are areas in which Cambridge Cognition can made a significant contribution in this current issue.

Enquiries:

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-review publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the CANTABmobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

Cambridge Cognition's product portfolio consists of: